{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:14:51Z","timestamp":1786994091617,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.medmal.2018.11.012","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T14:14:29Z","timestamp":1545401669000},"page":"505-510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Switching from abacavir\/lamivudine plus nevirapine to abacavir\/lamivudine\/dolutegravir in virologically controlled HIV-infected adults (SWAD study)"],"prefix":"10.1016","volume":"49","author":[{"given":"C.","family":"Allavena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Volteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Andr\u00e9-Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Guimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Khatchatourian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Morrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Billaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rodallec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Reliquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Jovelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Le Guen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Perr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2018.11.012_bib0115","doi-asserted-by":"crossref","first-page":"e1001194","DOI":"10.1371\/journal.pmed.1001194","article-title":"CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE","volume":"9","author":"Young","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.medmal.2018.11.012_bib0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel","volume":"316","author":"Gunthard","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.medmal.2018.11.012_bib0125","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s40265-014-0256-y","article-title":"Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.medmal.2018.11.012_bib0130","series-title":"Summary of product characteristics","author":"Triumeq","year":"2014"},{"key":"10.1016\/j.medmal.2018.11.012_bib0135","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1128\/AAC.00292-13","article-title":"Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans","volume":"57","author":"Castellino","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2018.11.012_bib0140","first-page":"3307","article-title":"Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1","volume":"70","author":"Dailly","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2018.11.012_bib0145","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1023\/A:1013050904635","article-title":"Validation of the HIV treatment satisfaction questionnaire (HIVTSQ)","volume":"10","author":"Woodcock","year":"2001","journal-title":"Qual Life Res"},{"key":"10.1016\/j.medmal.2018.11.012_bib0150","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1524-4733.2006.00121.x","article-title":"Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version","volume":"9","author":"Woodcock","year":"2006","journal-title":"Value Health"},{"key":"10.1016\/j.medmal.2018.11.012_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2014.09.006","article-title":"A liquid chromatography-tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma","volume":"971","author":"Gregoire","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.medmal.2018.11.012_bib0160","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1016\/j.jchromb.2009.07.031","article-title":"A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV","volume":"877","author":"Martin","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.medmal.2018.11.012_bib0165","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1128\/AAC.03906-14","article-title":"Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants","volume":"59","author":"Cortez","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2018.11.012_bib0170","series-title":"55th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC). San Diego, California; September 17\u201321","article-title":"Switching to abacavir\/dolutegravir\/lamivudine fixed dose combination (ABC\/DTG\/3TC FDC) from a PI, INI or NNRTI based regimen maintains HIV suppression","author":"Trottier","year":"2015"},{"key":"10.1016\/j.medmal.2018.11.012_bib0175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/15284336.2017.1338844","article-title":"Switching to the single tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus co-formulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-NNRTI","volume":"18","author":"Pozniak","year":"2017","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.medmal.2018.11.012_bib0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.medmal.2018.11.012_bib0185","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/QAD.0b013e3283612419","article-title":"Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study","volume":"27","author":"Stellbrink","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2018.11.012_bib0190","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2125.2012.04440.x","article-title":"A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects","volume":"75","author":"Koteff","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.medmal.2018.11.012_bib0195","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/00002030-200112070-00008","article-title":"Nevirapine-containing antiretroviral therapy in HIV-1-infected patients results in an anti-atherogenic lipid profile","volume":"15","author":"van der Valk","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2018.11.012_bib0200","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48-week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2018.11.012_bib0205","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.medmal.2018.11.012_bib0210","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/00126334-200212153-00007","article-title":"Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature","volume":"31","author":"Ammassari","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.medmal.2018.11.012_bib0215","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/hiv.12280","article-title":"The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens","volume":"17","author":"Casado","year":"2016","journal-title":"HIV Med"},{"key":"10.1016\/j.medmal.2018.11.012_bib0220","unstructured":"Journal officiel de la R\u00e9publique Fran\u00e7aise no\u00a00132. Arr\u00eat\u00e9 du 8\u00a0juin 2015\u00a0modifiant l\u2019arr\u00eat\u00e9 du 17\u00a0d\u00e9cembre 2004\u00a0modifi\u00e9 fixant la liste pr\u00e9vue \u00e0 l\u2019article L.\u00a05126-4\u00a0de Code de la sant\u00e9 publique."}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X17308521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X17308521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:18:18Z","timestamp":1759972698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X17308521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0399077X17308521"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2018.11.012","relation":{},"ISSN":["0399-077X"],"issn-type":[{"value":"0399-077X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching from abacavir\/lamivudine plus nevirapine to abacavir\/lamivudine\/dolutegravir in virologically controlled HIV-infected adults (SWAD study)","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2018.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}